Who is sponsoring NCT01082796?

NCT01082796 is sponsored by Chinese Academy of Sciences.

What condition does NCT01082796 study?

NCT01082796 studies Genotype, Pharmacokinetic.

What is the status of NCT01082796?

NCT01082796 is currently COMPLETED.

Last reviewed 2010-03-08 · How we verify

Investigate the Relationship Between CYP2C19 Genetic Polymorphisms and Pharmacokinetics of Glipizide in Healthy Chinese Subjects

NCT01082796 NA COMPLETED

Diabetes mellitus is a growing global disease now and future, and in China, 1.2 million peoples per year have been diagnosed as diabetes mellitus. 90% diabetes mellitus patient is Type 2 diabetes mellitus. Glipizide is a potent drug to service patients who suffer from Type 2 disease. Little information has been presented for the relationship between CYP2C19 genetic polymorphism and glipizide, since recently the investigators reported that there existed a tendency. In this study the investigators found that CYP2C19 polymorphism significantly influenced the pharmacokinetics of glipizide.

Details

Lead sponsor	Chinese Academy of Sciences
Phase	NA
Status	COMPLETED
Enrolment	14
Start date	2009-11
Completion	2010-01

Conditions

Genotype
Pharmacokinetic

Interventions

Glipizide

Countries

China